BiVictriX Therapeutics plc

BiVictriX is an emerging drug discovery and development company generating a pioneering new class of next-generation anti-cancer therapeutics which exhibit superior selectivity towards the cancer. Existing antibody-based approaches have shown considerable therapeutic benefit in a number of cancer indications, however the wider application of these drugs to more challenging settings is limited by the shared expression of the targeted antigens on healthy tissues. Thus leading to debilitating and sometimes fatal toxic side-effects associated with treatment. The lack of true cancer specificity seen with existing platforms has resulted in many antibody-based therapeutics being removed from the clinic and is one of...

Bispecific adc therapeutics,immunotherapy,antibodies,drug discovery,oncology,leukaemia,drug development,and biotherapeutics

Bivictrix therapeutics plc operates in the Biotechnology research industry.

Bivictrix therapeutics plc's revenue is 11m - 100m

Bivictrix therapeutics plc has 11 - 50 employees.